

# **Visual-Functional Mismatch: FFR, Not CAG, Has Prognostic Value!!**

**Soo-Jin Kang, MD., PhD.**

Department of Cardiology, University of Ulsan College of Medicine  
Asan Medical Center, Seoul, Korea

# Disclosure Statement of Financial Interest



I, Soo-Jin Kang DO NOT have a financial interest /arrangement or affiliation with one or more organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this presentation

# DEFER Trial


## 325 Patients with Single Vessel Disease

- FFR  $\geq 0.75$  **DEFER** (91 pts)
- FFR  $\geq 0.75$  **PERFORM PCI** (90 pts)
- FFR  $< 0.75$  **REFERENCE** (144 pts)

### Cardiac Death and Acute MI after 5 Years




### % Patients Free from Chest Pain



*J Am Coll Cardiol* 2007;49:2105-11

# FAME: One Year Outcomes




Tonino et al. *New Engl J Med* 2009;360:213-24

# FAME 2

## FFR-Guided PCI vs. Medical Therapy in Stable CAD

### Primary Outcomes

**PCI+MT vs. MT:** HR 0.32 (0.19-0.53); p<0.001  
**PCI+MT vs. Registry:** HR 1.29 (0.49-3.39); p=0.61  
**MT vs. Registry:** HR 4.32 (1.75-10.7); p<0.001




No. at risk	0	1	2	3	4	5	6	7	8	9	10	11	12
MT	441	414	370	322	283	253	220	192	162	127	100	70	37
PCI+MT	447	414	388	351	308	277	243	212	175	155	117	92	53
Registry	166	156	145	133	117	106	93	74	64	52	41	25	13

\* Composite of all cause death, myocardial infarction, unplanned hospitalization with urgent revascularization

### Urgent Revascularization

**PCI+MT vs. MT:** HR 0.13 (0.06-0.30); p<0.001  
**PCI+MT vs. Registry:** HR 0.63 (0.19-2.03); p=0.43  
**MT vs. Registry:** HR 4.65 (1.72-12.62); p=0.009



No. at risk	0	1	2	3	4	5	6	7	8	9	10	11	12
MT	441	414	371	325	286	256	223	195	164	129	101	71	38
PCI+MT	447	421	395	356	315	285	248	217	180	160	119	93	53
Registry	166	156	145	133	117	106	94	75	65	53	42	26	13

# Deferral vs. performance of percutaneous coronary intervention of functionally non-significant coronary stenosis: 15-year follow-up of the DEFER trial

Frederik M. Zimmermann<sup>1</sup>, Angela Ferrara<sup>2</sup>, Nils P. Johnson<sup>3</sup>, Lokien X. van Nunen<sup>1,4</sup>, Javier Escaned<sup>5</sup>, Per Albertsson<sup>6</sup>, Raimund Erbel<sup>7</sup>, Victor Legrand<sup>8</sup>, Hyeong-Cheol Gwon<sup>9</sup>, Wouter S. Remkes<sup>10</sup>, Pieter R. Stella<sup>11</sup>, Pepijn van Schaardenburgh<sup>12</sup>, G. Jan Willem Bech<sup>13,14</sup>, Bernard De Bruyne<sup>2</sup>, and Nico H.J. Pijls<sup>1,4\*</sup>

	Defer	Perform	Reference	P (Defer vs. Perform)
Death at 15 years	30 (33.0%)	28 (31.1%)	52 (36.1%)	0.78
MI at 15 years	2 (2.2%)	9 (10.0%)	18 (12.5%)	0.033
TVR at 15 years	33 (36.3%)	25 (27.8%)	51 (35.4%)	0.22


Deferral of PCI of a functionally insignificant lesion is associated with a favorable very long-term outcomes without late 'catch-up'



# Fractional flow reserve versus angiography for guidance of PCI in patients with multivessel coronary artery disease (FAME): 5-year follow-up of a randomised controlled trial

Lokien X van Nunen\*, Frederik M Zimmermann\*, Pim A L Tonino, Emanuele Barbato, Andreas Baumbach, Thomas Engström, Volker Klauss, Philip A MacCarthy, Ganesh Manoharan, Keith G Oldroyd, Peter N Ver Lee, Marcel van't Veer, William F Fearon, Bernard De Bruyne, Nico H J Pijls, for the FAME Study Investigators

## Long-term safety of FFR-guided PCI that should be the standard of care in multivessel disease




# Visual-Functional Mismatch


(1129 lesions with DS >30%) who underwent IVUS and FFR

*IRIS-FFR ClinicalTrials.gov NCT01366404*

## 1066 Non-LM lesions



## 63 LM lesions




*Park et al. JACC interv 2012;5:1029-36*



# Visual-Functional Mismatch SB Stenosis

Jailed SB FFR 0.88




Post-stenting DS 50%

*Ahn et al. JACC Interv 2012;5:155-61*


# Frequency of QCA-FFR Mismatch

- Mismatch: QCA-DS > 50%, FFR  $\geq$  0.80
- Reverse-mismatch: QCA-DS  $\leq$  50%, FFR < 0.80



# IVUS-FFR Mismatch

	N	FFR	RLA	MLA	AUC	Sens	Spec	PPV	NPV	Accu
<b>Takaki</b> (1999 Circ)	51	0.75	9.3	<b>3.0</b>	—	83%	92%	—	—	—
<b>Briguori</b> (2001 AJC)	53	0.75	7.8	<b>4.0</b>	—	92%	56%	38%	96%	<b>64%</b>
<b>Ben-Dor</b> (2012 *)	205	0.80	8.6	<b>3.09</b>	0.73	69%	72%	—	—	<b>70%</b>
<b>Kang</b> (2011 Circ int)	236	0.80	7.6	<b>2.4</b>	0.80	90%	60%	37%	96%	<b>68%</b>
<b>Kang</b> (2012 AJC)	784	0.80	8.2	<b>2.4</b>	0.77	84%	63%	48%	90%	<b>69%</b>
<b>Koo</b> (2011 JACC int)	267	0.80	6.8	<b>2.75</b>	0.81	69%	65%	27%	81%	<b>67%</b>
<b>Gonzalo</b> (2012 JACC)	47	0.80	7.1	<b>2.36</b> IVUS	0.63	67%	65%	67%	65%	<b>66%</b>
<b>Gonzalo</b> (2012 JACC)	61	0.80	7.1	<b>1.95</b> OCT	0.70	82%	63%	66%	80%	<b>72%</b>



	p-value	Adjusted OR	95% CI
<b>MLA &lt; 2.4 but FFR ≥ 0.8 “Mismatch”</b>			
<b>Women</b>	0.048	1.450	1.003 – 2.095
<b>LAD location</b>	0.027	0.666	0.465 – 0.954
<b>Reference lumen diameter</b>	<0.001	0.298	0.204 – 0.437
<b>Distal (vs. proximal) segment</b>	0.002	2.021	1.293 – 3.159
<b>MLA ≥ 2.4 but FFR &lt; 0.8 “Rev-mismatch”</b>			
<b>Age</b>	<0.001	0.940	0.909 – 0.972
<b>LAD location</b>	0.071	2.256	0.932 – 5.460
<b>Plaque rupture</b>	<0.001	11.138	4.886 – 25.39

# Subgroup-specific MLA

544 intermediate lesions assessed in 516 pts from 24 centers  
FFR  $\leq 0.80$  in 169/544 lesions (31.1%) and 167/516 pts (32.4%)

	N	MLA cutoff	C-statistic	Accuracy
<b>All lesions</b>	544	2.9 mm <sup>2</sup>	0.66	66.0%
LAD	296	2.9 mm <sup>2</sup>	0.64	63.5%
LCX	110	2.4 mm <sup>2</sup>	0.72	77.3%
RCA	138	2.8 mm <sup>2</sup>	0.75	77.5%
Proximal	259	3.0 mm <sup>2</sup>	0.76	74.9%
Mid	195	2.6 mm <sup>2</sup>	0.63	65.6%
Distal	90	3.0 mm <sup>2</sup>	0.63	51.1%
RVD <3.0 mm	322	2.6 mm <sup>2</sup>	0.65	66.1%
RVD $\geq 3.0$ mm	219	3.0 mm <sup>2</sup>	0.71	72.6%
Length $\leq 12.3$ mm	272	3.0 mm <sup>2</sup>	0.67	64.7%
Length >12.3 mm	269	2.8 mm <sup>2</sup>	0.69	68.8%



# Why Mismatch

(1129 lesions with DS >30%) who underwent IVUS and FFR  
(ClinicalTrials.gov NCT01366404)

## Factors Affecting FFR

	Beta	p-value	95% CI
<b>Age</b>	0.008	<0.001	0.004 - 0.011
<b>LAD location</b>	-0.386	<0.001	-0.462 - 0.311
<b>Lesion length</b>	-0.006	<0.001	-0.009 - 0.003
<b>Minimal lumen area</b>	0.185	<0.001	0.149 - 0.222
<b>Plaque burden</b>	-0.006	<0.004	-0.009 - 0.003
<b>Plaque rupture</b>	-0.165	0.020	-0.302 - 0.027



# Multivariable Analysis Predicting FFR


## in 700 LAD lesions of 700 patients

\*Including age, female, body surface area, smoking, angiographic DS, minimal lumen diameter, lesion length, IVUS-MLA, plaque burden, averaged reference EEM area and %area stenosis, †addition of left ventricular mass

	Total (700 patients)*			608 patients with echo data†		
	$\beta$	p value	95% CI	$\beta$	p value	95% CI
Age	0.119	0.001	0.000–0.002	0.192	<0.001	0.001–0.002
<b>BSA</b>	<b>-0.111</b>	<b>0.002</b>	<b>-0.101– -0.024</b>			
<b>LV mass</b>				<b>-0.121</b>	<b>&lt;0.001</b>	<b>-0.001 – 0.000</b>
Angiographic DS	-0.185	<0.001	-0.002 – -0.001	-0.190	<0.001	-0.002 – -0.002
Lesion length	-0.110	0.001	-0.001 – 0.001	-0.077	0.027	-0.001 – 0.000
IVUS-MLA	0.312	<0.001	0.022 – 0.035	0.294	<0.001	0.019 – 0.032
Plaque burden	-0.115	0.002	0.001 – 0.000	-0.157	<0.001	-0.002 – -0.001

*Kang S-J et al. J Am Coll Cardiol Intv 2013;6:562-8*

# Independent Factors of LM FFR<0.80





Sensitivity 79%  
 Specificity 80%  
 PPV 83%  
 NPV 76%

	OR	P
<b>Model 1</b>		
Plaque rupture	4.47	0.014
BMI, kg/m <sup>2</sup>	1.19	0.05
Age, yrs	0.95	0.031
MLA, mm <sup>2</sup>	0.37	<0.001
<b>Model 2 (echo-LV mass)</b>		
LV mass, g	1.01	0.03
Age, yrs	0.94	0.021
MLA, mm <sup>2</sup>	0.34	<0.001


Park SJ et al. JACC Interv 2014;7:868–74

# Plaque Rupture



Complex or irregular lumen produces greater flow resistance and energy loss of fluid, thus resulting in pressure drop and FFR↓

*Park et al. JACC interv 2012;5:1029-36*



# Summary

## Mechanisms of Visual-Functional Mismatch

### Stenosis Severity

Angiographic DS  
IVUS-MLA  
Plaque burden  
Lesion length

### Local Factor

Plaque rupture


### Myocardial Territory

Age  
Gender  
LAD vs. non-LAD  
Proximal segment  
Ref vessel diameter  
Body surface area  
Body mass index  
LV mass

*AMC data*




# Impact of Myocardial Territory on FFR

Myocardial area subtended to the artery distal to the stenosis evaluated by angiography using a modified APPROACH score




<b><i>Predictors of FFR&lt;0.80</i></b>	<b>OR</b>	<b>95% CI</b>	<b>P value</b>
<b>Minimum lumen diameter</b>	0.031	0.013–0.076	< 0.001
<b>Lesion length</b>	1.038	1.009–1.069	0.001
<b>Myocardial size (<i>modified APPROACH</i>)</b>	1.113	1.079–1.147	< 0.001





$V_{\text{sub}} = 55\text{cc}$ ,  $V_{\text{ratio}} = 46\%$



$V_{\text{sub}} = 29\text{cc}$ ,  $V_{\text{ratio}} = 26\%$




# Clinical and CAMS Data

Age, years	62.5±9.2
Men	64 (89%)
Body mass index, kg/m <sup>2</sup>	25.1±2.6
<b><i>CAMS data</i></b>	
Total LV myocardial volume, cc	120.3±26.1
Myocardial volume of LM territory, cc	79.4±26.9
Myocardial volume of RCA territory, cc	32.1±11.9
Myocardial volume of LAD territory, cc	52.1±14.8
Myocardial volume of LCX territory, cc	34.1±11.5
%Myocardium of RCA territory, %	27.2±8.2
%Myocardium of LAD territory, %	43.9±7.3
%Myocardium of LCX territory, %	28.8±7.9


# Diagnosis of Ischemia-producing Lesions by Using IVUS-MLA and CAMS

## Determinants of $FFR \leq 0.75$

$V_{sub} > 30.7cc$



$V_{ratio} > 25.4\%$




$V_{sub}$  : myocardial volume subtended by stenotic segment  
 $V_{ratio}$  : Ratio of  $V_{sub}$  to total LV myocardial volume

# Prediction of $FFR \leq 0.75$

$V_{sub} > 30.7cc$


MLA cut-off  $\leq 2.85mm^2$



Sensitivity 85%  
Specificity 92%  
PPV 92%  
NPV 85%

$V_{sub} \leq 30.7cc$

MLA cut-off  $\leq 2.67mm^2$



Sensitivity 100%  
Specificity 69%  
PPV 38%  
NPV 100%

In the setting of a larger myocardial territory, IVUS-MLA  $\approx 2.8mm^2$  accurately predicted an  $FFR \leq 0.75$ , while clinical relevance of the lesions with a smaller myocardium is limited

# Summary

- Clinical impact and prognostic value of FFR-guided PCI has been validated even at very long-term
- With a frequent visual-functional mismatch, either angiographic DS or IVUS-MLA poorly predicted FFR
- Functional significance is determined not only by stenosis severity but also by myocardial territories and collaterals
- CAMS-based assessment of myocardial size may improve the accuracy of IVUS prediction for ischemia